|Bid||6.37 x 800|
|Ask||6.35 x 800|
|Day's Range||6.13 - 6.48|
|52 Week Range||2.12 - 6.87|
|Beta (5Y Monthly)||-0.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 10, 2021 - Nov. 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.90|
BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.
LAVAL, Quebec, September 23, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough ("RCC") and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic prur
If you're looking for Canadian growth stocks to buy, these four Canadian companies are some of the best opportunities on the TSX today. The post 4 Canadian Stocks That Could Soar 68% or More According to Bay Street appeared first on The Motley Fool Canada.